The initiative will be conducted under the auspices of the COVID-19 Therapeutics Accelerator, which was established by the Gates Foundation, Wellcome, and Mastercard to hasten development of therapies for the disease.

Commercial manufacturing of Lilly's COVID-19 antibody therapy will begin in April 2021 at the Fujifilm Diosynth Biotechnologies facility in Denmark. Regulatory authorization for the treatment is pending, the company said; if it is received before April, Lilly will begin distributing the treatment to lower-income countries.

Lilly's collaborators -- AbCellera Biologics, Shanghai Junshi Biosciences, and Columbia University -- will waive royalties as part of this initiative, according to the firm.

Eli Lilly seeks EUA from FDA for its SARS-CoV-2 mAbs
Eli Lilly submitted an emergency use authorization (EUA) request from the U.S. Food and Drug Administration (FDA) for its SARS-CoV-2 monoclonal antibodies...

Amgen, Eli Lilly to scale up manufacturing of COVID-19 antibody therapies
Eli Lilly and Amgen will collaborate on global antibody manufacturing to significantly increase the supply capacity of Lilly's potential COVID-19 therapies.

Eli Lilly rolls out early COVID-19 antibody trial data
Eli Lilly released early data from a phase II clinical trial that explored the use of the neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting.

Eli Lilly, Innovent expand immuno-oncology licensing
Eli Lilly and Innovent Biologics have agreed to a global expansion of their strategic alliance for Tyvyt (sintilimab injection), an anti-programmed cell...

Lilly begins phase III trial of COVID-19 antibody treatment
Eli Lilly has begun a phase III trial of its lead COVID-19 antibody treatment candidate, Ly-CoV555.